Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma
RNA-seq (gene expression) · human · 36 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Kidney cancerThis series is part of our curated briefing on it.
- Samples
- 36 samples: 36 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE216495_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA894092 and SRA study SRP404283. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 36 sample titles: 36 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM6674926 A498 Sunitinib-resistant At treated replicate 1 [42At1]
- GSM6674927 A498 Sunitinib-resistant At treated replicate 2 [42At2]
- GSM6674928 A498 Sunitinib-resistant At treated replicate 3 [42At3]
- GSM6674929 A498 Sunitinib-resistant Av treated replicate 1 [42Av1]
- GSM6674930 A498 Sunitinib-resistant Av treated replicate 2 [42Av2]
- GSM6674931 A498 Sunitinib-resistant Av treated replicate 3 [42Av3]
- GSM6674932 A498 Sunitinib-resistant Dur treated replicate 1 [42Dur1]
- GSM6674933 A498 Sunitinib-resistant Dur treated replicate 2 [42Dur2]
- GSM6674934 A498 Sunitinib-resistant Dur treated replicate 3 [42Dur3]
- GSM6674935 A498 parental At treated replicate 1 [4_AT1]
- GSM6674936 A498 parental At treated replicate 2 [4_AT2]
- GSM6674937 A498 parental At treated replicate 3 [4_AT3]
- GSM6674938 A498 parental Av treated replicate 1 [4_AV1]
- GSM6674939 A498 parental Av treated replicate 2 [4_AV2]
- GSM6674940 A498 parental Av treated replicate 3 [4_AV3]
- GSM6674941 A498 parental Dur treated replicate 1 [4_DUR1]
- GSM6674942 A498 parental Dur treated replicate 2 [4_DUR2]
- GSM6674943 A498 parental Dur treated replicate 3 [4_DUR3]
- GSM6674944 786-O Sunitinib-resistant At treated replicate 1 [74At1]
- GSM6674945 786-O Sunitinib-resistant At treated replicate 2 [74At2]
- GSM6674946 786-O Sunitinib-resistant At treated replicate 3 [74At3]
- GSM6674947 786-O Sunitinib-resistant Av treated replicate 1 [74Av1]
- GSM6674948 786-O Sunitinib-resistant Av treated replicate 2 [74Av2]
- GSM6674949 786-O Sunitinib-resistant Av treated replicate 3 [74Av3]
- GSM6674950 786-O Sunitinib-resistant Dur treated replicate 1 [74Dur1]
- GSM6674951 786-O Sunitinib-resistant Dur treated replicate 2 [74Dur2]
- GSM6674952 786-O Sunitinib-resistant Dur treated replicate 3 [74Dur3]
- GSM6674953 786-O parental At treated replicate 1 [7_AT1]
- GSM6674954 786-O parental At treated replicate 2 [7_AT2]
- GSM6674955 786-O parental At treated replicate 3 [7_AT3]
- GSM6674956 786-O parental Av treated replicate 1 [7_AV1]
- GSM6674957 786-O parental Av treated replicate 2 [7_AV2]
- GSM6674958 786-O parental Av treated replicate 3 [7_AV3]
- GSM6674959 786-O parental Dur treated replicate 1 [7_DUR1]
- GSM6674960 786-O parental Dur treated replicate 2 [7_DUR2]
- GSM6674961 786-O parental Dur treated replicate 3 [7_DUR3]
- GSE174740 Drug repurposing identifies a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma 11 samples same disease briefing · shares sunitinib-resistant, renal
- GSE216494 Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro 12 samples same disease briefing · shares renal
- GSE193006 Transcriptome RNA sequencing data of sarcomatoid renal cell carcinoma cell line SRCC and its subclones with different phenotypes. 5 samples same disease briefing · shares renal
- GSE15641 Gene signatures of progression and metastasis in renal cell cancer 92 samples same disease briefing · shares renal
- GSE19982 Gene expression discriminates chromophobe renal cell carcinoma and oncocytoma 30 samples same disease briefing · shares renal
- GSE214635 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis 18 samples same disease briefing
- GSE223688 SETD2 loss sensitizes kidney cancer cells to DNA hypomethylating agents 6 samples same disease briefing
- GSE17895 Somatic Mutation Screen of Clear Cell RCC 160 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.